Gasiorowski K, Szyba K, Sawicka J, Gulanowski B
Department of Basic Medical Sciences, Medical Academy, Wroclaw, Poland.
Int J Occup Med Environ Health. 1995;8(3):267-73.
We have previously described that todralazine markedly decreased mutagenicity of several indirect- and direct-acting mutagens. In this paper we report the results of experiments conducted in order to evaluate the involvement of desmutagenic and bio-antimutagenic activities in the observed antimutagenic effect of todralazine. The results of the Ames test suggest a bio-antimutagenic, and not desmutagenic effect of todralazine. The separation of B(a)P and their derivatives by thin layer chromatography, performed after in vitro incubation of this promutagen with S9 fraction and todralazine revealed almost complete decline of B(a)P derived products in the presence of todralazine. The results indicate that the observed antimutagenic effect of todralazine on B(a)P mutagenicity is bio-antimutagenic rather than desmutagenic in their nature.
我们之前曾描述过，托屈嗪能显著降低几种间接和直接作用诱变剂的诱变性。在本文中，我们报告了为评估托屈嗪的抗诱变作用中去诱变和生物抗诱变活性所起的作用而进行的实验结果。艾姆斯试验的结果表明托屈嗪具有生物抗诱变作用，而非去诱变作用。在用该前诱变剂与S9组分和托屈嗪进行体外孵育后，通过薄层色谱法对苯并[a]芘及其衍生物进行分离，结果显示在存在托屈嗪的情况下，苯并[a]芘衍生产物几乎完全减少。结果表明，托屈嗪对苯并[a]芘诱变性的抗诱变作用本质上是生物抗诱变而非去诱变作用。
